Research
Hormonal
Therapeutic strategies to reduce TMAO levels, including broad-spectrum antibiotics, dietary restriction of precursors, and specific inhibitors like 3,3-dimethyl-1-butanol (DMB), can attenuate atherosclerosis and cardiovascular risk.
Inhibiting TMA production (e.g., via DMB found in some vinegars/oils) or reducing choline/carnitine intake may lower TMAO and protect against atherosclerosis in animal models. Human applications are not yet standard.
GoodSupportsHIGH confidence
A number of therapeutic strategies are being explored to reduce TMAO levels, including use of oral broad spectrum antibiotics, promoting the growth of bacteria that utilize TMAO as substrate and the development of target-specific molecules with varying level of success.
Why this rating
Strong preclinical evidence; clinical application is still emerging.
Source
Trimethylamine N-Oxide: The Good, the Bad and the Unknown
Manuel Velasquez et al. · Toxins · 2016
DOI 10.3390/toxins8110326
narrative_reviewCited 496×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Dietary intake of choline and L-carnitine leads to the gut microbial production of Trimethylamine (TMA), which is converted by host liver enzymes (FMO3) into Trimethylamine N-oxide (TMAO).Strong
- Elevated plasma levels of Trimethylamine N-oxide (TMAO) are associated with an increased risk of major adverse cardiovascular events, atherosclerosis, and mortality in patients with chronic kidney disease.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →